Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Sections
Personal tools
Log in
 
You are here: Home › Collaborative Groups › G.I. and Other Associated Cancers Research Group › Discovered GP73 as a classifier of HCC in high risk patients and demonstrated that it improves AFP performance in detecting early stage HCC.

Discovered GP73 as a classifier of HCC in high risk patients and demonstrated that it improves AFP performance in detecting early stage HCC.

GP73 was approved for HCC screening in China in combination with AFP.
Announcement